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Abstract 18 
This study assessed pneumococcal carriage in the early periods after routine use of 13-valent 19 
pneumococcal conjugate vaccine (PCV13) in Hong Kong. Nasopharyngeal swabs were 20 
obtained from 1110 children (<5 years) admitted with acute illness during September 21 
2010-August 2013. Pneumococcal carriage rate was 13.5% in unvaccinated children, 14.1% 22 
in children who had ≥1 PCV dose and 15.3% in children who had ≥3 PCV doses. 23 
Nonv-PCV13 serotypes comprised 56.4% of all isolates. The most common serogroup/types 24 
were 15 (15A, 5.1%; 15B, 10.3%; 15C, 9.6%; 15F, 0.6%), 19F (17.9%), 6A (7.1%) and 6C 25 
(7.1%). Carriage of serogroup 15 was more common among vaccinated children (4.1% vs. 26 
0.6%, P=0.033). Molecular typing revealed that expansion of several clones (clonal complex, 27 
CC63, CC199, CC1262, CC3397) was responsible for the increase in serogroup 15. Almost 28 
all CC63 and CC3397 isolates were nonsusceptible to both penicillin and erythromycin. The 29 
finding highlights the emergence of serogroup 15 following PCV13 use.  30 
 31 
(150 words) 32 
 33 
  34 
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Introduction 35 
Routine use of 7-valent pneumococcal conjugate vaccine (PCV-7) has been followed by 36 
reductions in vaccine serotypes invasive pneumococcal disease (IPD) and nasopharyngeal 37 
carriage among children targeted for vaccination (Ho et al., 2006; Ho et al., 2011b; Miller et 38 
al., 2011). The IPD rates have also reduced in older children and adults through herd 39 
immunity (Miller et al., 2011). However, these benefits have been counteracted by increased 40 
rates of IPD and carriage with non-PCV7 serotypes, notably multidrug-resistant 19A (Moore 41 
et al., 2008). However, the factors affecting serotype replacement are complex (Mehr and 42 
Wood, 2012; Dagan, 2009). Post-PCV7 surveillances have found variability in the pace of 43 
serotype replacement and in the predominating nonvaccine serotypes (Mehr and Wood, 2012). 44 
Broader coverage is provided by the 10-valent and 13-valent pneumococcal conjugate 45 
vaccines (PCV10 and PCV13) which were first approved by the European Medicines Agency 46 
in January 2009 and by the Food and Drug Administration in the United States in February 47 
2010, respectively for use in children. In addition to the seven serotypes included in PCV7 (4, 48 
6B, 9V, 14, 18C, 19F and 23F), PCV10 contains serotypes 1, 5, 7F, and PCV13 contains 1, 3, 49 
5, 6A, 7F and 19A. PCV13 has been approved in 128 countries and at least 83 of them have 50 
put PCV13 into routine use for children (Chiba et al., 2014). Concerns have been raised that 51 
increasing use of PCV13 would drive a shift towards non-PCV13 serotypes in both IPD and 52 
carriage (Mehr and Wood, 2012). Nonetheless, information on the changes in serotype 53 
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distribution and antimicrobial susceptibilities of pneumococcal isolates in the post-PCV13 era 54 
is limited (Chiba et al., 2014; Zuccotti et al., 2014).    55 
In Hong Kong, PCV7 has been available in the market since October 2005 (Ho et al., 56 
2011a). PCV10 and PCV13 were later marketed in August 2009 and May 2010, respectively. 57 
In Asia, Hong Kong is one of the first cities to introduce PCV7 into the childhood 58 
immunization program and this was implemented since September 2009 (Ho et al., 2011a). 59 
From October 2010 onward, PCV7 was replaced by PCV10. This was mainly driven by 60 
vaccine cost consideration and the non-inferior safety and efficacy of PCV10 against IPD, 61 
when compared to PCV7. From December 2011 onward, PCV10 was replaced by PCV13 62 
(Ho et al., 2011b). No catch-up vaccination was arranged at the time of switching to PCV10 63 
and PCV13. For all formulations, the immunization schedule consists of a standard 64 
three-dose primary series (at 2, 4 and 6 months of age) and a booster dose at age 12-15 65 
months. Before its routine use in our children, PCV7 was available as a self-financed item 66 
and its uptake in the vaccine target population had been low (Ho et al., 2011b). Here, we 67 
investigated the further changes in pneumococcal carriage and of the serotypes and 68 
antimicrobial resistance in children aged <5 years from 2010 to 2013.  69 
 70 
2. Materials and method 71 
2.1 Study design and data collection 72 
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Nasopharyngeal swabs were collected from children aged <5 years hospitalized in a 73 
regional hospital from September 2010 to August 2013. A standardized questionnaire was 74 
used to obtain the following participant information from parents of participating children: 75 
demographic characteristics, number of siblings (and their ages), day care attendance, prior 76 
antibiotic treatment (in the last 3 months), current antibiotic treatment, smoking habit of 77 
family members, the physician’s diagnosis on the screening day, medical and immunization 78 
history (PCV7, PCV10 and PCV13). Young children aged <5 years who were hospitalized 79 
for acute illness (e.g. respiratory illness, diarrhea) were enrolled. Children with major 80 
underlying condition (e.g. immunosuppression, malignancy, chronic heart disease, chronic 81 
lung disease, chronic renal disease, diabetes mellitus) were excluded. The protocol is 82 
approved by the Institutional Review Board at the Hong Kong West Cluster/University of 83 
Hong Kong. 84 
2.2 Microbiological methods 85 
Nasopharyngeal cultures were obtained with alginate-tipped swabs (Ho et al., 2011b). 86 
All specimens were obtained by trained nurses. The swabs were transferred to the 87 
microbiology laboratory at the University of Hong Kong within 6 hours of collection in 88 
Amies transport media (TRANSWAB per nasal; Medical Wire and Equipment, Wilts, United 89 
Kingdom). For selective isolation of S. pneumoniae, nasopharyngeal swabs were inoculated 90 
onto 5% horse blood agar supplemented with gentamicin (2 g/ml) and incubated in 5% CO2 91 
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for 16 to 24 hours. The isolates were identified by colony morphology, Gram stain, optochin 92 
susceptibility, bile solubility and a slide co-agglutination test (Phadebact Pneumococcus Test, 93 
Remel). Susceptibility of the isolates was determined by Etest (penicillin, cefotaxime) or disc 94 
diffusion method (erythromycin) (Clincal and Laboratory Standard Institute, 2014). The 95 
criteria for penicillin-nonsusceptible and cefotaxime-nonsusceptible were ≥0.12µg/ml (oral 96 
penicillin breakpoint) and ≥2µg/ml (nonmeningitis breakpoint).  97 
2.3 Molecular studies 98 
The serotypes of the S. pneumoniae isolates were determined by multiplex PCR and the 99 
Quellung reaction (Ho et al., 2011a; Ho et al., 2011b). The isolates were initially tested by a 100 
sequential multiplex PCR approach (Pai et al., 2006). Strains that could not be serotyped and 101 
those that required further testing to the serotype level were then tested by the Quellung 102 
method with group, type and factor antisera from the Statens Seruminstitut (Copenhagen, 103 
Demark). Serotype 6C and 6D were identified by PCR assays (Ho et al., 2010). Multilocus 104 
sequence typing (MLST) was performed as previously described 105 
(http://pubmlst.org/spneumoniae/ ) and results were analyzed by eBURST v3 (Enright and 106 
Spratt, 1998).  107 
2.4 Statistical analysis 108 
The serotype coverage for the 7-valent and 13-valent PCVs for carriage isolates was 109 
calculated as the proportion of all isolates included in the vaccine formulations, without 110 
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taking into account the potential serogroup cross-protection. Potential risk factors for 111 
pneumococcal carriage were studied by univariate analysis using Chi square or Student’s t 112 
test. Variables that were significant in the univariate analysis and those that could increase 113 
the risk of carriage from a clinical point of view were further tested by logistic regression 114 
using the forward-conditional models. The following parameters were entered for analysis in 115 
the logistic regression models: age, gender, having sibling aged <5 years, having smoker in 116 
household, day care center (DCC) attendance, recent antibiotic use and any use of PCV. To 117 
further understand how pneumococcal carriage might have changed before and at different 118 
time periods after implementation of PCVs, selected data from this study was tabulated with 119 
those from two previous studies conducted by us (Chiu et al., 2001; Ho et al., 2011b). A P 120 
value of <0.05 was considered to indicate statistical significance. All statistical analysis was 121 
performed by the SPSS statistic package (version 20.0, SPSS Hong Kong Ltd., Hong Kong). 122 
 123 
3. Results 124 
3.1 Demographics 125 
A total of 1110 children were enrolled in the study. The mean age ( standard deviation 126 
[SD]) of the children was 1.7  1.2 years. The mean  SD household size was 3.6  1.3. 127 
Fifty-eight percent of the children were male. In this cohort of children, 29.6% had household 128 
siblings aged ≤5 years; 53.4% had recent antibiotic use; 27.6% had exposure to household 129 
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smokers and 86.0% had at least one dose of any PCVs (79.7% in 2010/2011, 86.3% in 130 
2011/2012 and 95.2% in 2012/2013). Among vaccinated children, 44.1% had ≥1 dose PCV7, 131 
39.1% had ≥1 dose PCV10, 29.9% had ≥1 dose PCV13 and 67.7% had ≥3 doses of any PCVs. 132 
Combination of >1 PCV formulations was received by 24.9% of the vaccinated children.  133 
3.2 Pneumococcal serotype distribution and antimicrobial susceptibilities 134 
Pneumococcal carriage was detected in 14.1% (156/1110) of the children (16.7% in 135 
2010/11, 12.5% in 2011/12, and 12.5% in 2012/13). Table 1 showed distribution of the 136 
serotypes and antimicrobial resistance. Overall, PCV13 serotypes accounted for 43.6% 137 
(68/156) and non-vaccine serotypes accounted for 56.4% (88/156). Four PCV13 serotypes 138 
including 1, 7F, 9V and 18C were not found. The common serotypes were 19F (17.9%), 15B 139 
(10.3%), 15C (9.6%), 6A (7.1%) and 6C (7.1%). Serogroup 15 accounted for 45.5% (40/88) 140 
of all non-vaccine isolates (including 15A, 9.1% [8/88]; 15B, 18.2% [16/88]; 15C, 17.0% 141 
[15/88] and 15F, 1.1% [1/88]). MIC50/MIC90 (range) of penicillin and cefotaxime for all the 142 
isolates were 0.125/4 g/ml (0.0024 µg/ml) and 0.125/4 µg/ml (0.00816 µg/ml), 143 
respectively. Isolates with penicillin (MIC ≥0.12µg/ml), cefotaxime (MIC ≥2µg/ml), 144 
erythromycin and dual penicillin/erythromycin nonsusceptibility were found among a wide 145 
range of different serotypes (Table 1). Eighteen isolates had penicillin MIC ≥4 µg/ml. They 146 
belong to serotypes 19F (n=11), 19A (n=2), 15C (n=2), 15B (n=1), 6C (n=1) and 34 (n=1).  147 
  148 
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3.3 Changes in serotypes of carried pneumococci over time  149 
The data from this study was tabulated with those from two previous studies (Table 2). 150 
Compared to the previous two groups of children, there was a small decline in overall 151 
pneumococcal carriage and antibiotic-resistant pneumococcal carriage rates. Prevalence of 152 
PCV7 serotypes progressively declined. In contrast, pneumococcal isolates of non-PCV13 153 
serotypes, especially serogroup 15 have increased in prevalence over time (Table 2). Within 154 
the three years in period 3, no significant trends in serotype replacement were observed. The 155 
prevalence of carriage of serogroup 15 was 3.6% in 2010/2011, 3.3% in 2011/2012 and 4.0% 156 
in 2012/2013 (P=0.883). Serogroup 15 accounted for 21.7% of all pneumococcal isolates in 157 
2010/2011, 26.4% in 2011/2012 and 32.4% in 2012/2013 (P=0.504).  158 
 159 
3.4 Pneumococcal carriage and PCV use  160 
In the current cohort (period 3), total pneumococcal carriage was not associated with 161 
pneumococcal immunization status. Carriage rate was 13.5% in unvaccinated children, 14.1% 162 
in children who had ≥1 PCV dose (P = 0.845) and 15.3% in children who had ≥3 PCV doses 163 
(P = 0.437). The effect of PCVs on pneumococcal carriage was further investigated by 164 
multivariate analysis. A history of PCV use was independently associated with lower carriage 165 
of PCV7 serotypes (P=0.042; odds ratio [OR], 0.5; 95% confidence interval [CI], 0.2 to 0.9) 166 
and higher carriage of non-PCV13 serotypes (P=0.025; OR, 2.9; 95% CI, 1.1 to 7.2). 167 
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Carriage of serogroup 15 was significantly more common among children with a history of 168 
PCV use (4.1% [39/955] vs. 0.6% [1/155], P=0.033). However, the association failed to 169 
reach statistical significance in the multivariate analysis (P=0.064, OR, 6.6; 95% CI, 0.9 to 170 
48.1). 171 
 172 
3.5 Changes in antimicrobial resistance and clonal structure of serogroup 15 isolates 173 
A total of 82 serogroup 15 isolates (serotype 15A, 17 isolates; 15B, 26 isolates; 15C, 35 174 
isolates; and 15F, 4 isolates) were obtained during the three time periods and all were 175 
investigated by MLST. The relationship between MLST and serogroup 15 subtypes was 176 
summarized in Table 3. An eBURST analysis of our isolates with all other serogroup 15 177 
isolates in the MLST database was shown in Figure S1 (supplementary file). In the three time 178 
period, either 15C or 15B was the most prevalent subtype. The isolates belonged to 24 179 
different sequence types (STs) of which 68 isolates belonged to five clonal complexes (CCs, 180 
with 6 to 27 isolates each) and 14 isolates were singletons (12 different STs). The prevalence 181 
of four clones had increased over time (Figure 1): CC199-serotype 15B/C clone, 1.3%, 2.6% 182 
and 8.3% (P < 0.001); CC1262-serotype 15B/C clone, 0%, 0.9% and 6.4% (P<0.001); 183 
CC63-serotype 15A/C/F clone, 0.3%, 1.4% and 5.8% (P < 0.001); and CC3397-serotype 184 
15B/C clone, 0%, 0.6% and 2.6% (P = 0.004) in period 1, period 2 and period 3, respectively. 185 
The nonsusceptibility rates among serogroup 15 isolates from period 1, period 2 and period 3 186 
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were 7.1%, 32.1% and 37.5% for penicillin (P = 0.102), 50.0%, 57.1% and 47.5% for 187 
erythromycin (P = 0.732), and 7.1%, 32.1% and 30.0% (P = 0.185) for dual 188 
penicillin/erythromycin nonsusceptibility, respectively. The penicillin- and 189 
erythromycin-nonsusceptibility rates by clonal groups were as follows: CC199-serotype 190 
15B/C, 11.1%/18.5%; CC63-serotype 15A/C/F, 80%/100%; CC1262-serotype 15B/C, 191 
7.7%/15.4%; CC156-serotype 15A/C/F, 14.3%/57.1%; CC3397-serotype 15B/C, 192 
100%/100% and singletons, 14.3%/71.4%. High level penicillin resistance (MIC ≥4 µg/ml) 193 
was observed in four isolates, three from period 3 and one from period 2. The isolates 194 
belonged to ST3397-serotype 15C (n=2), ST199-serotype 15B (n=1) and ST1262-serotype 195 
15C (n=1). 196 
  197 
4. Discussion 198 
 This study extends our previous observations on the changes in pneumococcal carriage, 199 
antimicrobial resistance rates and serotype distribution of nasopharyngeal isolates before and 200 
since the routine use of PCVs in our children (Ho et al., 2011b). The findings showed that 201 
overall carriage declined and was due mainly to a loss of PCV7 serotypes. At the same time, 202 
there was replacement with non-vaccine serotypes. We previously noted an increase in 203 
several PCV13-nonPCV7 (6A and 19A) and nonPCV13 serogroup/serotypes (6C, 23A and 204 
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15) among children from period 2 (Ho et al., 2011b). Here, we found that the incidences of 205 
6A, 19A and 6C have declined or stabilized following a switch to PCV13 for routine use.  206 
Of note, serogroup 15 isolates continued to rise and it is now the predominant colonizing 207 
serogroup/serotype. When all the subtypes of serogroup 15 are considered together, their 208 
prevalence had increased by 6.9 folds from 3.7% in 1999-2000 to 8.1% in 2009-2010 and 209 
25.6% in 2010-2013. In serially sampled Massachusetts communities, 15B/C had increased 210 
from 6% in 2001 to 11% in 2008-2009 following the widespread use of PCV7 (Wroe et al., 211 
2012). Among Pittsburgh-area’s children presenting with acute otitis media (Martin et al., 212 
2014), an increase in the carriage of serogroup 15 pneumococci was also noted. In 2012-2013 213 
(Martin et al., 2014), serogroup 15 (all subtypes) was the most frequently occurring 214 
serogroup/serotype comprising 23% of all colonizing pneumococcal isolates. At present, the 215 
clinical significance of the emergence of serogroup 15 in NP carriage is unclear. Previous 216 
studies found that serotype 1, 3, 5, 7F and 19A (total 7.7% in this study) have a high 217 
propensity to cause invasive disease while the ability of serogroup 15 to cause invasive 218 
disease is low (Del et al., 2014; Yildirim et al., 2010). In the post-PCV13 era, only small 219 
numbers of invasive pneumococcal disease were caused by serogroup 15 (Levy et al., 2014). 220 
In Japan where PCV7 vaccination in children began in 2010, an increase in the rate of 221 
pediatric invasive pneumococcal disease caused by 15A, 15B and 15C during 2010-2012 was 222 
noted (Chiba et al., 2014). In our locality, ongoing surveillance has not detected any increase 223 
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in the frequency of occurrence of serogroup 15 among children with invasive pneumococcal 224 
disease (Ho et al., 2011a).   225 
 Genotypic analysis of the serogroup 15 strains by MLST revealed that increasing 226 
prevalence of serogroup 15 was mainly caused by expansion of several preexisting clones 227 
(CC63-serotype 15A/C/F, CC199-serotype 15B/C, CC1262-serotype 15B/C and 228 
CC3397-serotype 15B/C). Two of them, CC63-serotype 15A/C/F and CC199-serotype 15B/C 229 
are internationally recognized clones designated by the Pneumococcal Molecular 230 
Epidemiology Network (http://web1.sph.emory.edu/PMEN/pmen_table1.html) as 231 
Sweden15A-25/ST63 and Netherlands15B-37/ST199, respectively. In the MLST database (last 232 
accessed 25 August 2014) CC/ST63 and CC/ST199 are the commonest genotypes associated 233 
with serotype 15A and 15B/C, respectively. Besides serogroup 15 subtypes, ST63 was also 234 
commonly associated with serotype 14, 19A and 19F, and ST199 associated with serotypes 3, 235 
6, 19A, 19F, 23A and 23F. Prior to the introduction of PCV13, ST199 is one of the major 236 
STs involved in the massive expansion of serotype 19A (Scott et al., 2012). ST1262 and 237 
ST3397 are minor genotypes among serogroup 15 strains in the MLST database. All ST3397 238 
strains deposited in the database were of serogroup 15 and all were recovered from patients in 239 
China (Li et al., 2011). As suggested previously (Scott et al., 2012), some STs may be 240 
preferentially favored in serotype replacement. This could occur as existing clones switch 241 
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their capsules or by expansion of preexisting STs with nonvaccine serotypes (Croucher et al., 242 
2013).   243 
 This study has some potential limitations. First, we studied a convenient sample of 244 
children hospitalized to a regional hospital. The fact that many children had history of recent 245 
antibiotic use may influence the results of this study. Therefore, caution is required in 246 
interpreting the findings involving comparisons with results from our previous territory-wide 247 
carriage studies (Chiu et al., 2001; Ho et al., 2011b). Second, the number of children with 248 
carriage was relatively small. Therefore, it was not possible to stratify the findings by age 249 
groups. Third, the methodology that we adopted for culture is not capable of detecting 250 
carriage of multiple serotypes. The strengths of this study include molecular typing of the 251 
serogroup 15 isolates, and analysis of the culture result against the vaccination history and 252 
other epidemiological data.  253 
 In conclusion, this study showed that nasopharyngeal carriage by previously prevalent 254 
pneumococcal vaccine serotypes have largely been replaced by non-PCV13 types, especially 255 
serogroup 15. The results demonstrate that expansion of preexisting clones was mainly 256 
responsible for the recent increase in serogroup 15. Future pneumococcal vaccines may need 257 
to be planned according to increasing serogroup 15.  258 
 259 
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Table 1 268 
Distribution of antimicrobial non-susceptible nasopharyngeal Streptococcus pneumoniae 269 
isolates according to serotypes, Hong Kong 2010-2013  270 
 Total   %. with resistance phenotyped 
 % n  Pen-NS Ctx-NS Ery-NS Pen/Ery-NS 
PCV13 typesa        
19F 17.9 28  78.6 53.6 92.9 71.4 
6A 7.1 11  63.6 0 100 63.6 
19A 5.1 8  87.5 37.5 87.5 87.5 
14 4.5 7  100.0 0 85.7 85.7 
23F 3.8 6  50.0 0 66.7 50.0 
6B 1.9 3  66.7 0 100 66.7 
3 1.9 3  0 0 33.3 0 
4 0.6 1  0 0 100.0 0 
5 0.6 1  0 0 0 0 
Non-PCV13 types        
15B 10.3 16  18.8 6.3 25.0 6.3 
15C 9.6 15  46.7 13.3 40.0 40.0 
6C 7.1 11  81.8 18.2 81.8 72.7 
15A 5.1 8  50.0 12.5 100.0 50.0 
23A 3.2 5  60.0 0 100.0 60.0 
34 2.6 4  75.0 25.0 25.0 25.0 
35B 2.6 4  50.0 0 0 0 
11D 1.3 2  0 0 50.0 0 
28A 1.3 2  0 0 100.0 0 
35A/C/42 1.3 2  0 0 100.0 0 
35F 1.3 2  0 0 50.0 0 
15F 0.6% 1  100.0 0.0 100.0 100.0 
Othersb 5.1 8  0 0 50.0 0 
NT 5.1 8  37.5 0 62.5 37.5 
Total 100.0 156  53.2 16.0 69.2 46.2 
a PCV7 serotypes were underlined. Four PCV13 serotypes including 1, 7F, 9V and 18C were 271 
not found. 272 
b Including one isolate each of the following eight serotypes: 11A, 13, 17F, 18A, 21, 22F, 29 273 
and 33F. 274 
d Penicillin-nonsusceptible (Pen-NS, MIC ≥0.12µg/ml), cefotaxime-nonsusceptible (Ctx-NS, 275 
MIC ≥2µg/ml); erythromycin-nonsusceptible (Ery-NS); dual penicillin/erythromycin 276 
-nonsusceptible (Pen/Ery-NS).     277 
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Table 2 278 
Comparison of selected characteristics of children and nasopharyngeal Streptococcus 279 
pneumoniae carriage, Hong Kong  280 
 Sampling timea P valueb 
 Period 1 Period 2 Period 3  
No. of children tested 1978 2221 1110 - 
Recent antibiotic use, % 50.1 30.6 53.4 <0.001 
Children with at least one dose of     
Any PCVs, % 0.0 28.1 86.0 <0.001 
PCV13, % 0.0 0.0 25.8 <0.001 
Children with pneumococcal carriage, %     
Any serotypes 19.4 15.6 14.1 <0.001 
PCV7 serotypes 12.8 8.6 4.1 <0.001 
PCV13-nonPCV7 serotypes 1.3 2.5 2.1 0.019 
Non-PCV13 serotypes 5.3 4.6 7.9 <0.001 
Serotype 6C 0.4 1.2 1.0 <0.001 
Serogroup 15 0.7 1.3 3.6 <0.001 
Antibiotic- resistant pneumococcal carriage, %     
Pen-NS 11.3 11.1 7.5 0.428 
Ery-NS 14.9 13.6 9.7 0.266 
Total no. of pneumococcal isolates 383 347 156 - 
Proportion of pneumococci, % all isolates     
PCV7 serotypes 66.1 54.8 28.8 <0.001 
PCV13-nonPCV7 serotypes 6.5 15.9 14.7 <0.001 
Non-PCV13 serotypes 27.4 29.4 56.4 <0.001 
Serotype 6C 1.8 7.8 7.1 0.001 
Serogroup 15 3.7 8.1 25.6 <0.001 
a Data for period 1 and period 2 were from two previous carriage studies involving healthy 281 
children aged ≤5 years attending kindergartens or day care centers (Ho et al., 2011b; Chiu et 282 
al., 2001) while period 3 involved children hospitalized in a regional hospital. The sampling 283 
times were as follows: period 1, December 1999-June 2000; period 2, September 2009-April 284 
2010; and period 3, September 2010-August 2013. 285 
b Chi Square for comparison of data in the three time periods. 286 
 287 
  288 
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Table 3 289 
Subtypes of serogroup 15 by pneumococcal clones and collection periods, Hong Kong 290 
Variable n Serotype, % by row 
  15A 15B 15C 15F 
Collection time      
Period 1 14 21.4 7.1 50.0 21.4 
Period 2 28 21.4 32.1 46.4 0.0 
Period 3 40 20.0 40.0 37.5 2.5 
Clones      
CC199a 27 0.0 48.1 51.9 0.0 
CC63 15 80.0 0.0 6.7 13.3 
CC1262 13 0.0 46.2 53.8 0.0 
CC156 7 57.1 0.0 14.3 28.6 
CC3397 6 0.0 16.7 83.3 0.0 
Singletonsb 14 7.1 42.9 50.0 0.0 
Total 82 20.7 31.7 42.7 4.9 
CC, clonal complex; ST, sequence type 291 
a The following STs were found in the CCs.: CC199 (ST199, 22 isolates; ST200, 3 isolates; 292 
ST1200, 1 isolate; ST9763, 1 isolate), CC63 (ST63, 15 isolates); CC1262 (ST1262, 13 293 
isolates); CC156 (ST2647, 2 isolates; ST5453, 2 isolates; ST6011, 1 isolate; ST1078, 1 294 
isolate; ST3280, 1 isolate); CC3397 (ST3397, 6 isolates).  295 
b Two STs (ST8914 and ST9765) has two isolates each. Ten STs had one isolate each: ST83, 296 
ST193, ST1835, ST2758, ST8496, ST9762, ST9764, ST9766, ST9767 and ST9768. 297 
New STs found for the first time in this study were underlined. 298 
  299 
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Figure 1 300 
Changes in the prevalence of Streptococcus pneumoniae serogroup 15 isolates according to 301 
clonal complexes and sampling periods, Hong Kong. The sampling times were as follows: 302 
period 1, December 1999-June 2000; period 2, September 2009-April 2010; and period 3, 303 
September 2010-August 2013. The serotypes of the clonal complexes (CCs) were labeled.  304 
 305 
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Figure S1. eBURST analysis showing the ST distribution of serogroup 15 isolates. A 381 
total of 849 serogroup 15 isolates including 767 isolates from the MLST database (accessed 382 
on 25 August 2014) and 82 isolates form the current study were included. The four major 383 
clonal clusters (CC) found in this study were indicated with arrows.  384 
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